1-7 of 7
William Senapedis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers

Husain Yar Khan, Misako Nagasaka, Amro Aboukameel, Osama Alkhalili, Md. Hafiz Uddin, Sahar F. Bannoura, Yousef Mzannar, Ibrahim Azar, Eliza W. Beal, Miguel E. Tobon, Steve H. Kim, Rafic Beydoun, Erkan Baloglu, William Senapedis, Bassel F. El-Rayes, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Mohammed Najeeb Al Hallak, Asfar S. Azmi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1422–1433.
https://doi.org/10.1158/1535-7163.MCT-23-0251
Published: 01 December 2023
View article titled, Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <em>KRAS</em><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
Open the PDF for Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <em>KRAS</em><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602

Kateryna Krytska, Kathryn Evans, Tara Pritchard, Matthew Tsang, Raymond Yung, Yael P. Mosse, Stephen W. Erickson, Yuelong Guo, Erkan Baloglu, Yosef Landesman, Kyle A. Jensen, William Senapedis, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock, John M. Maris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B14.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B14
Published: 01 January 2018
View article titled, Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602
Journal Articles

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma

Amro Aboukameel, Irfana Muqbil, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (1): 76–87.
https://doi.org/10.1158/1535-7163.MCT-16-0205
Published: 05 January 2017
View article titled, Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma
Open the PDF for Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth

Omran Abu Aboud, Ching-Hsien Chen, William Senapedis, Erkan Baloglu, Christian Argueta, Robert H. Weiss
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (9): 2119–2129.
https://doi.org/10.1158/1535-7163.MCT-16-0197
Published: 01 September 2016
View article titled, Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth
Open the PDF for Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth in another window
Includes: Supplementary data
Journal Articles

Abstract B198: Selinexor (KPT-330), a novel Selective Inhibitor of Nuclear Export (SINE) shows marked NF-kB inhibition and significant anticancer activity against Non-Small Cell Lung Cancer (NSCLC).

William Senapedis, Marsha Crochiere, Tami Rashal, Trinayan Kashyap, Boris Klebanov, Jean-Richard Saint-Martin, Ori Kalid, Sharon Shechter, Diego del Alamo, Mwanasha Hamuza, Gali Golan, Eran Shacham, Sharon Tamir, Dilara McCauley, Erkan Baloglu, Michael Kauffman, Sharon Shacham, Yosef Landesman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B198.
https://doi.org/10.1158/1535-7163.TARG-13-B198
Published: 01 November 2013
View article titled, Abstract B198: Selinexor (KPT-330), a novel Selective Inhibitor of Nuclear Export (SINE) shows marked NF-kB inhibition and significant anticancer activity against Non-Small Cell Lung Cancer (NSCLC).
Journal Articles

Abstract A188: SINE resistant fibrosarcoma cells reveal changes in profile of gene expression, but continue to be sensitive to combination treatment by proteasome inhibition.

Marsha L. Crochiere, Trinayan Kashyap, Jean-Richard Saint-Martin, Sharon Shechter, Ori Kalid, Eran Shacham, William Senapedis, Boris Klebanov, Sharon Tamir, Diego del Alamo, Mwanasha Hamuza, Gali Golan, Erkan Baloglu, Dilara McCauley, Michael Kauffman, Sharon Shacham, Yosef Landesman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A188.
https://doi.org/10.1158/1535-7163.TARG-13-A188
Published: 01 November 2013
View article titled, Abstract A188: SINE resistant fibrosarcoma cells reveal changes in profile of gene expression, but continue to be sensitive to combination treatment by proteasome inhibition.
Journal Articles

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

Roberto A. Salas Fragomeni, Hye Won Chung, Yosef Landesman, William Senapedis, Jean-Richard Saint-Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman, James C. Cusack
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (7): 1171–1179.
https://doi.org/10.1158/1535-7163.MCT-12-1171
Published: 07 July 2013
View article titled, CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Open the PDF for CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma in another window
Includes: Supplementary data